Research progress on CAR T-cell neurologic toxicity
10.13303/j.cjbt.issn.1004-549x.2021.04.029
- VernacularTitle:CAR-T细胞治疗引起中枢神经系统神经毒性机制的研究进展
- Author:
Yiran MA
1
;
Yuanqin ZHANG
1
;
Yiwen HAO
1
Author Information
1. Department of Blood Transfusion, the First Hospital of China Medical University, Shenyang 110001, China
- Publication Type:Journal Article
- Keywords:
chimeric antigen receptor (CAR) T-cell therapy;
neurologic toxicity;
pathophysiology
- From:
Chinese Journal of Blood Transfusion
2021;34(4):432-434
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor (CAR) T-cell therapy is an effective new treatment for hematologic malignancies. Currently, two CAR T-cell products have been approved for clinical use by the U. S. FDA. A barrier to widespread use of CAR T-cell therapy is post-infusion toxicity, including primarily cytokine release syndrome and neurologic toxicity, in which neurotoxicity is the main factor for incidence rate and mortality rate.As there is still a lack of pathophysiological research on this symptom, this review describes existing neurologic toxicity and insights into the pathophysiology of this syndrome, which provides new opportunities for targeted therapeutic interventions to modulate CAR T-cell therapy toxicities.
